Table 1.

Demographic, clinical and experimental information for all of the involved brain tumor patients.

Patient data						Data acquisition of ai-fMRI		Dose of awake anesthesia
Patient no.	Sex/age(y)	Tumor location	Pathology	WHO grade	Extent of resectiona	Intraoperative performanceb	Blocks	Propofolc	Remif-Entanild
1	M/47	L temporal, parietal	Anaplastic oligodendroglioma	III	Total	Good	3	1.0	0.015
2	M/31	L frontal, insula	Astrocytoma	II	Subtotal	Good	3	1.6	0.020
3	F/40	L frontal, insula	Astrocytoma	II	Subtotal	Good	4.5	1.7	0.020
4	F/48	L insula	Astrocytoma	II	Total	Good	4.5	1.7	0.015
5	M/27	L insula	Astrocytoma	II	Subtotal	Failed (right hand)	3	1.0	0.030
6	M/58	L temporal, parietal	Glioblastoma	IV	Total	Failed (right hand)	4.5	0.8	0.020
7	F/51	L precentral gyri	Astrocytoma	II	Total	Good	6	1.3	0.015
8	M/31	L frontal, insula	Anaplastic astrocytoma	III	Subtotal	Good	6	1.3	0.020
9	M/26	L frontal, insula	Glioblastoma	IV	Total	Weaker (right hand)	6	1.0	0.020
10	M/44	L frontal	Astrocytoma	II	Total	Failed (right hand)	4.5	1.6	0.015
11	F/39	R frontal	Astrocytoma	II	Total	Weaker (left hand)	4.5	1.5	0.015

ai-fMRI = “awake” intraoperative functional MRI; WHO = World Health Organization.

^aThe extent of resection was determined by volumetric analysis. Total was defined as 100% resection of the tumor volume based on T2-FLAIR or T1 contrast. Subtotal was defined as greater than 90%.

^bGood means the bilateral hands normally and equally moved. Failed (with the failed side) means that the hand indicated in parenthesis could not move. Weaker (with the weaker side) means that the hand indicated in parenthesis could not move as intensely and strongly as the other hand.

^cPropofol was administered using a target-controlled infusion (TCI) technique. The effect-site concentrations (μg ml^− 1) before discontinuation for ai-fMRI were shown in this column.

^dThe maintenance doses of remifentanil (μg kg^− 1 min^− 1) during ai-fMRI scan.